Development of Pre-Clinical Assays for Quality Control of Cancer Imaging Agents
ISEF · 2024 Cellular and Molecular Biology
Overview
Glioblastoma is the most aggressive primary brain tumor, with an average survival of 14.6 months even with treatment. Prior research has shown that a protein, PTPµ, is cleaved in tumor tissue, and the abundant fragments allow them to serve as a tumor biomarker. Glioblastoma rapidly proliferates, making it difficult for surgeons to fully resect the tumor. Peptides derived from a short portion of PTPµ’s amino acid sequence are thought to bind to the fragments. By conjugating these peptides to fluorophores, surgeons can better identify what they need to resect. Using two in vitro assays, a bead aggregation assay and a fluorescent bead binding assay, we evaluated the effects of buffer conditions on peptide-protein interactions. Additionally, we sought to identify optimal conditions for peptide binding to PTPµ in hopes of improving clinical imaging agents for glioblastoma resection. With the bead aggregation assay, we found that particular types of media support the best aggregation. There is also a possible effect of pH on aggregation. When moving onto the fluorescent bead binding assay, preliminary research suggests that certain peptides have a strong affinity to PTPµ. Many more buffer conditions and peptides will be tested in future research to determine the conditions under which the peptides have the strongest binding to PTPµ, so they may be used as imaging agents.
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2026
Development of Peptide-Drug Conjugates Targeting Glioblastoma Cells
CSEF · 2006
Micropathology Lab Device for Detecting Molecular Lesions of Glioblastoma
CSEF · 2008
Microfluidic Image Cytometry to Detect PI3K Pathway Markers in Brain Cancer
CWSF · 2026
Brain-Penetrating Bioconjugate M13-CTX-PEP-1 for Targeted Glioblastoma Therapy In Silico
CSEF · 2013
Assessing a Targeted Heptapeptide as a Molecular Imaging Agent for Colorectal Cancer Screening
CSEF · 2016
Accelerating Cancer Immunotherapy: Optimization of an EGFRvIII-based Cancer Vaccine for Improved Glioblastoma Prognosis
ISEF · 2016
Designing a Novel Technique to Determine Patient Suitability for Brain Cancer Clinical Trials
CSEF · 2018
The Application of Exosomes for Diagnostics and Prognostics in Brain Tumors: Medulloblastoma and Glioblastoma
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair